BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 13, 2010
View Archived Issues
Javelin Ending Myriad Merger; Gets Better Deal from Hospira
Read More
Legal 'Markmanship' at Play in Cubist/Teva Generic Fight
Read More
FDA Holds an 'Opening Day' as PDUFA V Debate Begins
Read More
ChemGenex's Omapro Delayed Pending Companion Diagnostic
Read More
Stock Movers
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Financings Roundup
Read More
Appointments And Advancements
Read More
Mersana Inks $334M Teva Deal for Long-Acting Cancer Drug
Mersana Therapeutics Inc. is expected to announce on Tuesday a $334 million deal with Teva Pharmaceuticals Industries Ltd. for XMT-1107, a preclinical revival of the old antiangiogenic drug fumagillin. (BioWorld Today)
Read More